PepGen IncPEPG
Price$2.21

Qualitative Analysis

Business overview

Business Overview

PepGen Inc. (Nasdaq: PEPG) is a clinical-stage biotechnology company dedicated to advancing the next generation of oligonucleotide therapies. The company leverages its proprietary Enhanced Delivery Oligonucleotide (EDO) platform, which utilizes cell-penetrating peptides engineered to optimize tissue delivery and cellular uptake of therapeutic oligonucleotides. This technology is designed to address severe neuromuscular and neurological genetic diseases. Following strategic pipeline reprioritizations, PepGen's primary clinical focus is on myotonic dystrophy type 1 (DM1), a rare, inherited, life-shortening muscle-wasting disease with no currently approved FDA therapies.

Research as of 19 Jun 2026

Strategic Initiatives

Growth programs, investments, and their expected impact

AI-assisted
FREEDOM2-DM1 Clinical DevelopmentInnovation

Advancing the Phase 2 multiple ascending dose (MAD) clinical trial of PGN-EDODM1, a peptide-conjugated oligonucleotide candidate, in patients with myotonic dystrophy type 1 (DM1).

Expected impact: Aims to restore normal splicing function of MBNL1 and halt, slow, or reverse the progression of DM1.

Sign in / Sign up to read more
InvestmentR&D expenses remained elevated to support clinical programs, though tightly managed (R&D expenses were $13.0 million for Q1 2026).
TimelineOngoing, with 10 mg/kg cohort data expected in H2 2026 and 12.5 mg/kg cohort data expected in 2027.
Global Clinical Trial ExpansionExpansion

Expanding the geographic footprint of clinical trials by securing regulatory clearances and opening active sites internationally.

Expected impact: Accelerates patient recruitment and ensures diverse clinical trial populations.

Sign in / Sign up to read more
InvestmentPart of global clinical operations budget.
TimelineOngoing; regulatory clearances received in South Korea, Australia, and New Zealand, with active sites in Canada, the UK, and South Korea.

Mergers, Acquisitions & Partnerships

Recent deals and strategic collaborations

AI-assisted

Strategic Partnerships

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.